Cytosolic extracts from a human lymphoblastoid B-cell line, RPMI-8392, established from a patient with acute lymphocytic leukemia, contain two major forms of cyclic nucleotide phosphodiesterase (PDE): Ca2+-calmodulin dependent PDE (PDE1) and cAMP-specific PDE (PDE4 
in these cells in a sequence specific manner. This suggests that PDEs, particularly PDElBl, because its expression is selective, may be useful targets for inducing the death of leukemic cells.
In lymphocytes, cAMP has negative effects on proliferation and cell function (1) . Early studies by Tomkins and colleagues (2, 3) , using an S49 mouse lymphoma cell line, had shown that cAMP induces these cells to undergo reversible G, arrest, followed by cytolysis. Mutants resistant to cAMP-induced death were deficient in cAMP-dependent protein kinase, indicating that this enzyme functions in cAMP-induced cytolysis (2, 3) . More recent studies have shown that the death induced by cAMP is apoptotic cell death, and it occurs in normal, as well as transformed, lymphoid cells (4) (5) (6) (7) .
Selective elevations of cAMP levels in transformed lymphocytes could provide a means to selectively induce apoptosis in these cells. One means of elevating cAMP levels in cells is through the inhibition of cyclic nucleotide phosphodiesterase (PDE) activity. PDE is an isozymic family composed of many different types, grouped into seven broad gene families: Ca2+-calmodulin (CaM)-dependent (PDE1), cGMP-stimulated (PDE2), cGMP-inhibited (PDE3), cAMP-specific (PDE4), cGMP-specific (PDE5), photoreceptor (PDE6), and higher affinity cAMP-specific (PDE7) PDEs (8) . Early studies from our laboratory showed that PDE activity is greatly increased in actively growing and transformed lymphocytes (9) , that PDE activity is induced in human peripheral blood lymphocytes (HPBL) following mitogenic stimulation (9, 10) , and that PDE inhibitors profoundly inhibit mitogenic stimulation of HPBL (10, 11) . Initial characterizations of PDE in HPBL suggested it was comprised mainly of PDE4 activity (reviewed in ref. 11) , and recent cloning analysis shows expression of PDE4 mRNA in HPBL (12) . More recent biochemical analysis of PDE in purified human T lymphocytes using ion exchange HPLC separation (13, 14) , and in HPBL by sensitivity to selective PDE inhibitors (15) , gives evidence for the presence in these cells of PDE3, as well as PDE4, and inhibitors of PDE3 and PDE4 act synergistically to inhibit proliferation in both human (14) and rat (16) T lymphocytes. The presence of PDE7 in cultured human T lymphocytes was also recently shown by HPLC separation and cloning techniques (17, 18) . We documented the presence of PDE1 activity in a human Blymphoblastoid cell line isolated from a patient with acute lymphocytic leukemia, and showed that PDE1 activity is absent in normal, resting HPBL (19) . Others using bovine PBL confirmed an absence of PDE1 activity in resting PBL and showed its appearance in these cells following mitogenic stimulation (20) . Characterization with monoclonal antibodies suggested that the induced PDE1 activity in bovine PBL belongs to the PDE1B, 63-kDa Ca2+-CaM-dependent PDE gene family (20) .
Recently, the cDNA for PDElB1 has been cloned from bovine (21), rat (22) , and mouse (23) brain cDNA libraries. The expression of the mRNA for PDElB1 in different tissues as assessed by Northern blot analysis showed it to be restricted largely to brain, where it is enriched in the striatum (21) (22) (23) . Its expression in the T-lymphoma cell line, S49, was also shown (22) . In brain, PDElB1 mRNA is expressed as a single species of -3-4 kb (21-23), whereas in mouse S49 cells three transcripts are seen at 4.4, 7, and 12 kb (22) .
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MATERIALS AND METHODS
Growth and Maintenance of Cells. The B-cell lines RPMI-8392, RPMI-1788, and Daudi and the T-cell lines NA and JB,  were established from patients and provided by other investigators. The T-cell lines Jurkat and MOLT 4 were obtained from the American Type Culture Collection. HPBL were isolated from 60 ml of freshly drawn blood from normal donors by defibrination with glass beads and separation of the lymphocytes by Ficoll/Hypaque density gradient centrifugation, as described (10) . When stimulated by mitogen, HPBL were suspended in RPMI 1640 medium supplemented with 10% autologous serum, 100 units/ml penicillin, 100 ,tg/ml streptomycin, 2 mM L-glutamine, and stimulated with 10 gg/ml PHA-P (Sigma) for 3 days. Production (19) . The PDE1 gene family is comprised of at least three different genes, some producing alternate spliced forms as well (8, 25, 26 (1996) sponding to regions spanning from nt -23 to 834 and from nt 729 to 1611 of PDElB1 were generated and sequenced, and together they encompass the full ORF of the human form of PDElB1. Attempts to do RT-PCR using degenerate primers corresponding to regions of the 3'-untranslated sequence did not produce a product and, thus, a degenerate primer corresponding to the last 25 bp of the 3' end of the ORF (Fig. 2) was used instead. The sequence of this 3' end of the ORF and the 3'-untranslated sequence were obtained by PCR of a human brain cDNA library. As shown in Fig. 2 (19) . The effect of pharmacological inhibition of each of these PDE activities on induction of apoptosis in RPMI-8392 cells was tested, using the appearance of oligonucleosome length fragments of endonuclease-digested DNA as a measure of apoptosis. As shown in Fig. 3 , vinpocetine, a selective inhibitor of PDE1 (27) , induced apoptosis in these cells at concentrations .30 ,uM; rolipram and RO 20-1724, selective inhibitors of PDE4 (27) , each induced apoptosis at concentrations .10 ,uM. The effects of these inhibitors on PDE activity was examined in whole cell homogenates of RPMI-8392 cells. As seen in Fig. 4 , these inhibitors significantly inhibited PDE activity in RPMI cells at the concentrations at which they produced apoptosis. PDE inhibition appeared to plateau at s60% with PDE1 and =40% with PDE4 inhibitors; however, when added together, the effects of these inhibitors were not completely additive, suggesting that an additional form(s) of PDE may account for some of the activity in these cells. Treatment of other cell lines, which by RT-PCR were shown to express PDElB1 mRNA were as follows: RPMI-1788, Daudi, MOLT-4, NA, and Jurkat, as well as a human T-lymphoma cell line, JB, with 100 ,uM of vinpocetine-induced apoptosis in every one of these cell types (data not shown). (Fig. 2) , an 18-bp phosphorothioate antisense oligodeoxynucleotide (AS ODN) was synthesized, starting from 6 bp to the 5' end of the translation initiation codon and extending over the first four codons of the ORF. As a control, a nonsense oligodeoxynucleotide (NS ODN) containing the same base composition, but in a random, scrambled order, was also synthesized. These synthetic phosphorothioate ODNs were added to RPMI-8392 cells in concentrations from 0.3-30 ,uM; and the cells were examined for apoptosis. As shown in Fig. 5 , 48 hr treatment with 30 ,uM of AS ODN clearly induced apoptosis in these cells, whereas 30 ,uM of NS ODN did not. When cells were examined for apoptosis at 1, 2, and 3 days after addition of AS and NS ODNs, it was found that after 3 days, AS ODN induced apoptosis at both 10 ,tM and 30 ,tM, whereas in all cases, NS ODN had no effect (Fig. SB) .
Effect of Antisense on Expression of PDElBl mRNA and Enzymatic Activity. Using quantitative RT-PCR, the effect of AS ODN and NS ODN on the level of mRNA for PDElB1 in RPMI-8392 cells was examined. As seen in Fig. 6 , the level of mRNA for PDElB1 is diminished, relative to control, 1 day after treating cells with 10 ,uM and 30 ,uM of AS ODN, and absent after 2 days. The levels of ,B-actin mRNA, measured as a control, were unaltered by AS ODN. NS ODN had no effect Inhibition of PDE activity in RPMI-8392 cells by PDE inhibitors. PDE activity in whole cell homogenates of RPMI-8392 cells was tested for sensitivity to inhibition by vinpocetine, RO 20-1724, and rolipram, as indicated. Cells were grown to a density of about 106/ml, collected by centrifugation (1200 x g, 10 min), resuspended in 1 ml of homogenization buffer containing 40 mM Tris-HCl (pH 7.5), 1 mM EDTA, 1 mM DTT, 35 ,tg/ml phenylmethylsulfonyl fluoride, 15 mM benzamidine, 1 ,Lg/ml leupeptin, 1 ,ug/ml antipain, 1 jig/ml pepstatin, and 1 ,ug/ml aprotinin, homogenized with 20 strokes of a Dounce glass-on-glass homogenizer and assayed for PDE activity, using 1 ,uM cAMP as substrate, as described (19) . Data Blockage of PDE activity by the selective PDE1 inhibitor, vinpocetine, or blockage of the expression of the gene for PDElB1 by treatment with AS ODN led to apoptosis of these cells. RPMI-8392 cells, which also contain PDE4, are also induced to undergo apoptosis by specific PDE4 inhibitors. This suggests that both PDE4 and PDE1 may both serve to regulate a common pool of cAMP in these cells. A similar conclusion was reached for the actions of PDE3 and PDE4 in human lymphocytes, based on their synergistic effects on inhibition of lymphocyte proliferation (13, 14) .
Use of AS ODNs to block the expression of specific genes involved in growth regulation of lymphoid cells is gaining widespread interest as a result of the potential for such an approach to provide a novel therapeutic strategy for treatment of leukemias (29) . Inhibition of proliferation and/or induction of apoptosis in leukemic cells has recently been demonstrated by using AS ODNs targeted to bcl-2 (30), p53 (31), bcr-abl (32), c-myb (33), c-myc (34) , c-kit (35), c-fes (36), raf-1 (37), and IL-10 (38). Anti-c-myb (39) and bcl-2 (40) AS ODNs were also shown to increase the survival time of severe combined immunodeficient mice transplanted with human leukemic cells. With the exception of anti-bcr-abl AS ODN, which can be targeted to a leukemia-specific sequence in chronic myelogenous leukemia cells resulting from a chromosomal translocation (32) , all other AS ODNs used in this manner have the capability to block normal cellular functions, since the targeted genes are also expressed in normal cells as well.
The approach of using anti-PDE AS ODN to induce apoptosis of leukemic cells, as demonstrated in this study, has the potential to be selective for leukemic cells. Although PDE4 could be used as a therapeutic target, as demonstrated by the ability of rolipram and RO 20-1724 to induce apoptosis of RPMI-8392 cells, PDE4 is clearly present in normal, resting HPBL (10) (11) (12) and has a widespread distribution in tissues throughout the human body (41) . Similarly, although PDE7 has recently been shown to be expressed in cultured human T cells (17, 18) , analysis of tissue distribution of PDE7 show it to be fairly widespread and to predominate in skeletal muscle (42) . We have concentrated instead, therefore, on PDElB1 as a target, because, as shown in this study, the mRNA for PDElB1 is selectively expressed in leukemic and actively growing lymphocytes, and not in resting HPBL. Moreover, the expression of PDElB1 in tissues other than activated or transformed lymphocytes is largely restricted to areas of the brain (21) (22) (23) 
